Radiolabeled monoclonal antibody for the treatment of patients with B cell non-Hodgkin’s lymphomas with relapsed or refractory low-grade follicular or transformed B cell NHL, including patients with rituximab refractory follicular disease.
High response rates and durable responses in above lymphomas with a regimen that takes 7-9 days.